Diversified Trust Co Has $2.65 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Diversified Trust Co reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 12.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,705 shares of the biopharmaceutical company’s stock after selling 4,860 shares during the quarter. Diversified Trust Co’s holdings in Gilead Sciences were worth $2,649,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in shares of Gilead Sciences by 1.4% during the second quarter. The Manufacturers Life Insurance Company now owns 4,188,890 shares of the biopharmaceutical company’s stock valued at $322,838,000 after buying an additional 56,363 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Gilead Sciences by 1.5% during the second quarter. Commonwealth Equity Services LLC now owns 346,600 shares of the biopharmaceutical company’s stock valued at $26,713,000 after purchasing an additional 5,266 shares in the last quarter. Abundance Wealth Counselors bought a new position in shares of Gilead Sciences during the third quarter valued at about $1,881,000. Toronto Dominion Bank lifted its position in shares of Gilead Sciences by 66.6% during the third quarter. Toronto Dominion Bank now owns 1,288,884 shares of the biopharmaceutical company’s stock valued at $96,589,000 after purchasing an additional 515,191 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its position in shares of Gilead Sciences by 50.6% during the second quarter. Itau Unibanco Holding S.A. now owns 3,713 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 1,247 shares in the last quarter. 82.33% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $73.69 on Friday. The company has a 50 day moving average of $77.13 and a 200 day moving average of $77.45. The stock has a market cap of $91.80 billion, a P/E ratio of 16.38, a P/E/G ratio of 0.96 and a beta of 0.18. Gilead Sciences, Inc. has a 12 month low of $71.37 and a 12 month high of $87.86. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. Gilead Sciences’s revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.67 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.07 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be issued a $0.77 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.18%. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 8,242 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total value of $702,465.66. Following the transaction, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 8,242 shares of the stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the transaction, the insider now directly owns 82,729 shares in the company, valued at approximately $7,050,992.67. The disclosure for this sale can be found here. Insiders have sold 15,242 shares of company stock valued at $1,277,726 in the last quarter. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Oppenheimer dropped their price target on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, February 12th. Barclays lowered their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Wells Fargo & Company lowered their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Finally, Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $85.36.

Check Out Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.